

AMENDMENT

In the Claims:

Please amend the claims as follows:

Please cancel claims 1-28 and 35-43 as directed to non-elected inventions.

Please replace the presently pending claims with the following claims:

9/02
A1
29. (Amended) A method to identify a biological sample that exhibits dysregulated cellular growth comprising comparing the level of 20P2H8 gene expression in the biological sample to the level of 20P2H8 gene expression in a corresponding normal sample, wherein an alteration in the level of 20P2H8 gene expression in the biological sample as compared to the normal sample identifies the biological sample as exhibiting dysregulated cellular growth.

30. (Amended) A method of identifying the presence of a neoplasm in a biological sample comprising:
(a) determining a level of 20P2H8 gene expression in a test biological sample; and
(b) comparing the level of 20P2H8 gene expression in the test biological sample to a level of 20P2H8 gene expression found in a comparable normal biological sample,
wherein a difference in the level of 20P2H8 gene expression in the test biological sample relative to the normal biological sample identifies the presence of the neoplasm.

✓
Please cancel claim 31.

9/02
A2
32. (Amended) A method of diagnosing the presence of cancer in an individual comprising:
(a) determining the level of 20P2H8 gene expression in a test sample obtained from the individual; and
(b) comparing the level so determined to the level of 20P2H8 gene expression in a comparable known normal tissue sample,
wherein elevated 20P2H8 gene expression in the test sample relative to the normal tissue sample diagnoses the presence of cancer.

Please cancel claim 33.

A3 34. (Amended) The method of claim 32, wherein the cancer is prostate, cervical, kidney, stomach, skin, pancreatic, colon, bladder, breast, lung, testicular or ovarian cancer, and the test and normal tissue samples are selected from the group consisting of prostate tissue, kidney tissue, cervical tissue, skin tissue, stomach tissue, colon tissue, bladder tissue, breast tissue, lung tissue, pancreatic tissue, rectal tissue, ovarian tissue, testicular tissue, lymphatic tissue, serum, blood and semen.

Please add the following claims:

A3 44. (New) The method of claim 29, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

45. (New) The method of claim 44, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

46. (New) The method of claim 44, wherein the level of 20P2H8 gene expression is determined by measuring the level of 20P2H8 protein.

A4 47. (New) The method of claim 46, wherein the level of said protein is determined by contacting the samples with an antibody or fragment thereof immunoreactive with 20P2H8 protein.

48. (New) The method of claim 47, wherein said antibody is a polyclonal antibody.

49. (New) The method of claim 47, wherein said antibody is a monoclonal antibody.

50. (New) The method of claim 30, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

51. (New) The method of claim 50, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

52. (New) The method of claim 50, wherein the level of 20P2H8 gene expression is determined by measuring the level of 20P2H8 protein.

53. (New) The method of claim 52, wherein the level of said protein is determined by contacting the samples with an antibody or fragment thereof immunoreactive with 20P2H8 protein.

54. (New) The method of claim 53, wherein said antibody is a polyclonal antibody.

55. (New) The method of claim 53, wherein said antibody is a monoclonal antibody.

56. (New) The method of claim 32, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

57. (New) The method of claim 56, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

58. (New) The method of claim 56, wherein the level of 20P2H8 gene expression is determined by measuring the level of 20P2H8 protein.

59. (New) The method of claim 58, wherein the level of said protein is determined by contacting the samples with an antibody or fragment thereof immunoreactive with 20P2H8 protein.

60. (New) The method of claim 59, wherein said antibody is a polyclonal antibody.

61. (New) The method of claim 59, wherein said antibody is a monoclonal antibody.